Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.

ABSTRACT:

Objective

The purpose of this study was to determine whether metformin promotes weight loss in overweight outpatients with chronic schizophrenia or schizoaffective disorder.

Method

In a double-blind study, 148 clinically stable, overweight (body mass index [BMI] ≥27) outpatients with chronic schizophrenia or schizoaffective disorder were randomly assigned to receive 16 weeks of metformin or placebo. Metformin was titrated up to 1,000 mg twice daily, as tolerated. All patients continued to receive their prestudy medications, and all received weekly diet and exercise counseling. The primary outcome measure was change in body weight from baseline to week 16.

Results

Fifty-eight (77.3%) patients who received metformin and 58 (81.7%) who received placebo completed 16 weeks

SUBMITTER: Jarskog LF 

PROVIDER: S-EPMC3874085 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature